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OBJECTIVES: Cutaneous malignant melanoma (MCM) is a
major concern for health care providers and its incidence is
increasing. We systematically reviewed published articles
describing the impact on quality-of-life (QOL) of drugs for
MCM management, and all available economic analyses that
focused on this disease. METHODS: We searched secondary
databases including Medline, Embase, CINAHL, Cochrane, and
DARE from inception to 2006 using MESH terms “melanoma”
and “metastases”. Results were then combined with terms con-
cerning economic analyses (i.e., cost analysis, cost beneﬁt analy-
sis, cost control, cost savings, cost of illness, etc.), and quality of
life studies (i.e., quality adjusted life years, health status, QOL,
and QALY). Economic articles were assessed for quality utiliz-
ing the scale described by Iskedjian et al. RESULTS: Our search
strategy found 7 economic and 13 QOL studies. Economic
studies comprised 4 cost-effective analyses (CEAs), 2 burden of
illness studies (COIs), and 1 cost-utility analysis (CUA). All eco-
nomic studies scored >80% in quality. No strong evidence was
presented for cost-effectiveness of interferons in UK or Canada,
or for temazolomide in US. Screening for melanoma was not
cost-effective in US or Germany. Cost studies found the major-
ity of costs (90%) accrued in Stages 3&4. From the 13 QOL
studies, 8 measured baseline QOL, 6 of which studied the same
population, and generated similar results but with different
approaches (i.e., outcome measures). Tools used included GLQ-
8, QLQ-C30, QLQ-36, QWB-SA, and SF-36. Baseline scores
QOL scores ranged from 0.60–0.69. Another 5 studies (N = 959
patients) were randomized trials analyzing QOL in patients
treated with DTIC alone, DTIC ± interferon, DTIC + fotemus-
tine, interleukin ± histamine, and temozolomide. Little difference
was found in QOL scores between drugs or between baseline
and endpoint. CONCLUSIONS: Costs are substantial. Cost-
effectiveness has not been shown for screening or treatment of
MCM. Generally, no signiﬁcant improvements in QOL were
found for any alternative for treating MCM.
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DIFFERENTIAL ITEM FUNCTIONING USING RASCH ANALYSIS
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OBJECTIVES: The aim of the study was to test items for Dif-
ferential Item Functioning (DIF) in a condition-speciﬁc measure
for women having an abnormal screening mammography.
METHODS: The draft version of a 33-item condition-speciﬁc
measure was completed by 184 women who had received an
abnormal screening mammography and two weeks later by the
same women after having either a known false-positive result, a
diagnosed breast cancer or still undiagnosed. The measure was
also completed by 240 women with a normal screening result.
Data were analysed using the Rasch model. DIF relative to
person covariates was checked by analyses of variance examin-
ing the degree to which individual residuals for speciﬁc items
depended on the covariates. Absence of evidence of interaction
between the covariates and the estimated trait parameters were
taken as evidence of DIF being uniform. If uniform DIF was iden-
tiﬁed; mean scores of the dimension were estimated from the
means of the person locations on the latent trait according to
DIF found. RESULTS: One of six items in a dimension measur-
ing “sense of dejection” had uniform DIF in two of four sub-
groups. After deleting this item the remaining items still ﬁtted
the Rasch model with no DIF. In a 2-item dimension describing
the impact on breast examination both items had uniform DIF.
The ﬁrst item had uniform DIF relative to women diagnosed with
breast cancer and the second item had uniform DIF relative to
women with normal screening mammography. There was dif-
ference in the mean of the subscales’ raw score and the estimated
scores calculated according to identiﬁed DIF. CONCLUSION: If
an item functions differently in subpopulations and it is decided
to keep the item in a subscale; special precautions should be
taken when calculating scores of this dimension. Otherwise, 
the difference between subpopulations could be under or 
overestimated.
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OBJECTIVES: Capecitabine is an orally administered prodrug
of ﬂuorouracil, which is used for the treatment of colorectal and
breast cancer patients. Since patients take this drug usually at
home a high adherence to the prescribed dosage regimen is a
major prerequisite for therapeutic efﬁcacy. METHODS: Adher-
ence to capecitabine chemotherapy was assessed using
MEMS(TM)-vials. The closures of the vials are equipped with
an integrated micro-electronic circuit registering every opening
and closing. With the corresponding software the medication
events of the particular patient can be displayed on a computer
and evaluated. Percentage of correctly administered doses of
medication (i.e. registered openings of the MEMS(TM)-vial at
the correct time), and dosage (i.e. opening) intervals were deﬁned
as main outcome measures. RESULTS: We assessed the adher-
ence to capecitabine chemotherapy (taken twice daily for 14 days
with a 7 days break between the cycles) in 20 patients (14 breast
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and 6 colorectal cancer) over a mean period of 44.3 treatment
days (Range = 14 to 79 days, Median = 44.3 days, SD = 18.9
days). Overall adherence varied from 85.5% to 100% (Mean =
96.7%, Median = 98.9%, SD = 4.3%). The actual vial opening
intervals among the studied patients varied from 1.6 hours to
18.9 hours (Mean = 12.0 h, Median = 12.0 h, SD = 1.7 h, includ-
ing only days with actual twice daily opening). CONCLUSIONS:
Although the results show in general a high degree of overall
adherence and interval regularity, there were several individuals
who exhibited major discrepancies that may potentially endan-
ger therapeutic goals. The adherence data demonstrated here
form the basis for a prospective, open, controlled, two-armed
observational study investigating the impact of pharmaceutical
care as a multidisciplinary patient-oriented service on adherence
and other relevant clinical, subjective and economic outcome
parameters in a larger patient population.
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OBJECTIVES: Chemotherapy induced nausea and vomiting
(CINV) has a negative impact on HRQoL, but little empirical
data showing relation between failure to control CINV and QoL
aspects other than directly related physical symptoms are avail-
able. The aim is to study dimensions of HRQoL more inﬂuenced
by emesis. METHODS: Prospective, multi-center, observational
study on 325 naïve patients recruited at 8 Spanish Oncology Ser-
vices. Consecutive patients undergoing 1st cycle with moderate
to highly emetogenic chemotherapy and scheduled antiemetic
treatment based on granisetron or ondansetron were enrolled.
After chemotherapy (day 0), daily maximum nausea intensity
and number of vomiting episodes were recorded during 5 more
days in a diary card and then FLIE and EORTC QLQ-C30 were
self-administered. Acute CINV was deﬁned as developed in day
0, and delayed CINV as developed or persisting in days 1–5.
Antiemetic “complete” response was deﬁned as: no emesis and
no/mild nausea. RESULTS: Complete response (CI95%) against
acute and delayed CINV were reported by 78.5% (74.0–83.0%)
and 50.0% (44.5–55.0%) of patients. Response rate was not
related to emetogenicity of chemotherapy (p > 0.05). Physical
Functioning, Dyspnoea, Constipation, Diarrhoea and Financial
Diﬁculties from QLQ-C30 were not sensitive to antiemetic
response against CINV (p > 0.05). Reliability of FLIE improved
when the 4-inverted VAS items were discarded, but discrimina-
tion between antiemetic response groups was maintained. Better
response rates were obtained, in the granisetron arm, in the
dimensions Constipation, Nausea and Vomiting of QLQ-C30
and Vomiting scale of FLIE (p < 0.05). A cost minimization
analysis of CINV global antiemetic treatment reﬂects higher
treatment costs rates in the ondansetron arm. CONCLUSIONS:
Complete CINV prevention agrees with literature but evidence
of association between response rate and emotogenicity of
chemotherapy was not found. Both QLQ-C30 and FLIE were
sensitive to type of response showed by the patients. Reliability
of FLIE Spanish version may be improved.
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OBJECTIVES: As an outcome measure for pharmacoeconomic
studies, quality adjusted life year (QALY) is often used. Though
some indirect measurement tool have been proposed, it is not
widely used in clinical trials in Japan. We started QOL data col-
lection along with a clinical trial on breast cancer treatment
(National Surgical Adjuvant Study of Breast Cancer: N-SAS
BC02). The trial has been supported by Comprehensive Support
Project for Oncology Research and Health Outcomes Research.
The aim of this study is to measure QOL of patients receiving
adjuvant chemotherapy after surgery and investigate the validity
of QOL measurement. METHODS: N-SAS BC02 is a random-
ized controlled trial of AC(adriamycin+cyclophosphamide) and
taxanes. Though main outcome measures are disease-free sur-
vival and overall survival, QOL and economic consequences are
secondary concerns. Quality of life was surveyed 6 times during
one year from 300 samples of participants. We adopted EQ-5D
and visual analogue scale (VAS) as utility measurement. We used
Japanese Tariff for calculate utility score from EQ-5D. We also
used Functional Assessment of Cancer Therapy (FACT) for ref-
erence. RESULTS: Average utility score was 0.806 (SD = 0.161)
from EQ-5D. VAS result showed average of 0.744 (SD = 0.189).
Correlation coefﬁcient of EQ-5D and VAS was 0.47. CON-
CLUSIONS: Many participants have problems in dimensions of
Pain/Discomfort and Anxiety/Depression.
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OBJECTIVES: Existing reports of utility values for second-line
advanced non-small cell lung cancer (NSCLC) vary quite widely
and are not optimal for use in health technology assessments
within the UK. The aim of this study was to elicit UK societal-
based utility values for different tumour response statuses and
different grade 3 and 4 toxicities commonly associated with
NSCLC chemotherapy treatments. METHODS: Toxicities con-
sidered were neutropenia, febrile neutropenia, fatigue, diarrhoea,
nausea and vomiting, rash and hair loss. Each health state
described the symptom burden of disease and impact on differ-
ent levels of functioning (physical, emotional, sexual, and social).
The disutility related to each response status and toxicity was
estimated and combined to give health state values. Existing
health state descriptions of metastatic breast cancer were revised
to make them suitable as descriptions of NSCLC patients receiv-
ing second-line chemotherapy. The existing health states were
used in cognitive debrief interviews with oncologists (n = 5) and
oncology specialist nurses (n = 5). Changes were made as sug-
